$ cat ./records/gates-foundation-awards-40-million-to-fred-hutchinson-for-hiv-vac-2006.txt
Gates Foundation Awards $40 Million to Fred Hutchinson for HIV Vaccine Development
[RECORD.TXT] · cat --full
The Gates Foundation awarded $40 million to the Fred Hutchinson Cancer Center in Seattle to accelerate HIV vaccine research through the HIV Vaccine Trials Network (HVTN). The grant enabled HVTN to conduct Phase I, II, and III clinical trials across 20-plus countries, recruiting tens of thousands of participants in the highest-prevalence regions. HVTN became the largest publicly funded HIV vaccine trial network in the world, and the Fred Hutch collaboration became a cornerstone of Gates's long-term HIV vaccine strategy.
Source: https://www.fredhutch.org/en/news/releases/2006/07/gates.html
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Co-Founds Alliance for a Green Revolution in Africa (AGRA)
Next →
Awarded $10 million to UNHCR for the return and reintegration of refugees in South Sudan
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.